Clinical Trials Logo

Schistosomiasis Mansoni clinical trials

View clinical trials related to Schistosomiasis Mansoni.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06055530 Not yet recruiting - Clinical trials for Schistosomiasis Mansoni

Evaluation of an AI-DP for STH Deworming Programs: a Study Protocol

KAKADU
Start date: October 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to test a new AI diagnostic tool for detection, specification and quantification of parasitic infections (Ascaris, Trichuris, hookworm and S. Mansoni) in School aged children in Ethiopia and Uganda. The main questions it aims to answer are: - Diagnostic Performance of the AI tool and compare to traditional manual microscopy - Repeatability and reproducibility of the AI tool and compare to traditional manual microscopy - Time-to-result for the AI tool - Cost efficiency for the AI tool and traditional manual microscopy to inform programmatic decisions. - Usability of the AI tool Participants will be asked to provide a stool sample for examination by the AI tool and traditional manual microscopy. Participants with a positive test result will receive the proper treatment (Deworming drug).

NCT ID: NCT01541631 Not yet recruiting - Anemia Clinical Trials

A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes

Start date: May 2012
Phase: N/A
Study type: Interventional

In this study, it is hypothesized that helminth infections modulate immune responses against HIV-1 infection resulting into increased HIV-1 multiplication, faster progression to AIDS and increased episodes of AIDS-related opportunistic infections. Furthermore, the effect of helminth infections on progression of HIV-1 infection is dependent on helminth infection intensity, host background immunity, nutritional status, demographic factors and socio-economic status. Also, treatment of helminth infections using praziquantel and albendazole among HIV-1 infected individuals will lead to reduction in HIV-1 viral loads, improvement of CD4+ counts, CD4+/CD8+ ratio and Hb levels, improved weight gain and reduction of episodes of HIV-1 related opportunistic infections. In addition, HIV-1 infection is associated with poor anthelminthic treatment outcome as compared to non-HIV infected individuals